Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA.
J Oncol. 2010;2010:740472. doi: 10.1155/2010/740472. Epub 2010 Jan 14.
Ovarian cancer is the most common cause of mortality of tumors from gynecologic origin and is often diagnosed after patients have already progressed to advanced disease stage. The current standard of care for treatment of ovarian cancer includes cytoreductive surgery followed by adjuvant chemotherapy. Unfortunately, many patients will recur and ultimately die from their disease. Targeted therapies have been evaluated in ovarian cancer as a method to overcome resistant disease. Angiogenesis inhibitors have shown success in many tumor types and have also demonstrated promise in trials involving patients with ovarian cancer. PARP inhibitors may be potentially active agents in patients with BRCA-associated ovarian cancer. Trials that have evaluated combinations of targeted agents have often revealed untoward toxicities, thus tempering enthusiasm for this approach.
卵巢癌是妇科肿瘤死亡的最常见原因，通常在患者已经进展到晚期疾病阶段后才被诊断出来。目前，卵巢癌的治疗标准包括细胞减灭术，然后进行辅助化疗。不幸的是，许多患者会复发，最终死于疾病。靶向治疗已被评估为治疗卵巢癌的一种方法，以克服耐药性疾病。血管生成抑制剂在许多肿瘤类型中已显示出成功，并且在涉及卵巢癌患者的试验中也显示出了希望。PARP 抑制剂可能是 BRCA 相关卵巢癌患者的潜在有效药物。评估靶向药物联合治疗的试验常常显示出不良的毒性，从而降低了对这种方法的热情。
